April 21 (Reuters) - The U.S. Food and Drug Administration has approved Merck's (MRK.N), opens new tab once-daily, oral, combination regimen for HIV infections, the drugmaker ‌said on Tuesday, giving ...

The human immunodeficiency virus (HIV) attacks the body’s immune system; if left untreated, it can lead to AIDS — a late stage of infection that occurs when the immune system is severely compromised ...

By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...

The drug regulator has ordered all 4,153 licensed blood banks to register on a national portal by Wednesday, as the ...

Appointment supports revenue quality and profitability momentum as the Company activates its transformed operating base - Company announces ...

The State Department last week published ⁠data showing that the number of people being tested for HIV dropped sharply last year amid interruptions to PEPFAR, which has been credited with saving 26 ...

As Lord’s Mark prepares to operationalize exports, the approval not only strengthens its international market entry but also ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, ...

HIV pre-exposure prophylaxis (PrEP) uptake remains suboptimal among adolescents and young adults in the United States, ...

Merck (NYSE:MRK) received FDA approval for IDVYNSO, a once daily, two drug HIV 1 regimen that is non INSTI and tenofovir free. The new regimen showed non inferior efficacy to the current standard of ...

SHELTON, CT / ACCESS Newswire / May 15, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it ...